XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution.
It has been a busy start to 2020 for XPhyto and it was quick to move amid the global coronavirus crisis
Health
XPhyto Therapeutics partner 3A revives grant from German Ministry of Education and research
Health
Full interview: XPhyto sees Germany as key market as they announce deal with Oettinger Brauerei
